A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma

Bortezomib therapy has proven successful for the treatment of relapsed, relapsed/refractory, and newly diagnosed multiple myeloma (MM). At present, bortezomib is available as an intravenous injection, and its prolonged treatment is associated with toxicity and development of drug resistance. Here we...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Chauhan, Dharminder, Singh, Ajita V., Aujay, Monette, Kirk, Christopher J., Bandi, Madhavi, Ciccarelli, Bryan, Raje, Noopur, Richardson, Paul, Anderson, Kenneth C.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2010
Assuntos:
Lymphoid Neoplasia
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3321748/
https://ncbi.nlm.nih.gov/pubmed/20805366
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2010-04-276626
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados